OOIR: Observatory of International Research

Papers

(The H4-Index of AIDS is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
The need to avert emergent resistance to dolutegravir in children and adolescents with HIV	55
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy	53
Elevated stress-responsive biomarkers are associated with HIV acquisition in young women in rural South Africa	48
Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabine	46
Strategies for managing weight gain associated with antiretroviral therapy: switch or add?	46
Systemic inflammation in pregnant women with HIV: relationship with HIV treatment regimen and preterm delivery	43
Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV	35
Reduced bone density accrual among peripubertal boys with HIV in Zimbabwe: Erratum	34
Keeping up with Streptococcus pneumoniae in children living with HIV: Erratum	34
Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy	33
Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV	32
A new frontier in HIV care: the predictive power of renal biomarkers on heart health	32
Gut microbiota and plasma metabolites associated with bone mineral density in women with or at risk of HIV infection	28
Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure – two nationwide, population-based cohort studies	28
Quantifying missed opportunities for tuberculosis among people with HIV in the US President's Emergency Plan for AIDS Relief	28
Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort	27
Cerebral toxoplasmosis in the twenty-first century	26
Real world use of dolutegravir two drug regimens	26
Associations between social determinants of health and comorbidity and multimorbidity in people of black ethnicities with HIV	26
Virtual case management: a differentiated approach to HIV prevention, treatment, and care	26
Life expectancy of people with HIV on antiretroviral therapy in Spain	25
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin	24
Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France	23